Genprex, Inc. (GNPX): Price and Financial Metrics
GNPX Price/Volume Stats
Current price | $2.71 | 52-week high | $46.00 |
Prev. close | $2.74 | 52-week low | $2.50 |
Day low | $2.50 | Volume | 50,400 |
Day high | $2.90 | Avg. volume | 83,026 |
50-day MA | $5.40 | Dividend yield | N/A |
200-day MA | $15.31 | Market Cap | 4.03M |
GNPX Stock Price Chart Interactive Chart >
Genprex, Inc. (GNPX) Company Bio
Genprex, Inc., a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome. The company was founded in 2009 and is based in Austin, Texas.
Latest GNPX News From Around the Web
Below are the latest news stories about GENPREX INC that investors may wish to consider to help them evaluate GNPX as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time for a breakdown of the biggest pre-market stock movers as we check out all of the hottest news on Thursday morning! |
Genprex Granted Orphan Drug Designation in Small Cell Lung CancerLOS ANGELES, CA - (NewMediaWire) - November 23, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.Genprex was granted orphan drug designation by the FDA... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning! |
Genprex to Present at BIO-Europe 2023LOS ANGELES, CA - (NewMediaWire) - November 03, 2023 - (InvestorBrandNetwork via NewMediaWire) - IBN, a multifaceted financial news, content creation and publishing company, is utilized by both public and private companies to optimize investor awaren... |
Genprex to Present at BIO-Europe 2023 ConferenceGenprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its Executive Vice President, General Counsel and Chief Strategy Officer, Catherine Vaczy, will be providing an overview of the Company's gene therapies for cancer and diabetes at the upcoming BIO-Europe 2023 Conference taking place in Munich, Germany. |
GNPX Price Returns
1-mo | -35.48% |
3-mo | -70.54% |
6-mo | -82.84% |
1-year | -92.47% |
3-year | -98.40% |
5-year | -95.64% |
YTD | -70.54% |
2023 | -84.14% |
2022 | 10.69% |
2021 | -68.43% |
2020 | 1,196.88% |
2019 | -70.91% |
Loading social stream, please wait...